Intellia Therapeutics' NTLA-2002 Shows Promise With Potential Stock Surge
Intellia Therapeutics, Inc. (NTLA) the Most Promising Biotech Stock According to Hedge Funds?
BMO Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $70
Express News | Intellia Therapeutics Inc : Leerink Partners Cuts Target Price to $60 From $68
Intellia Therapeutics Announces New Date for Upcoming Investor Webcast
Intellia Therapeutics Inc (NTLA) Q2 2024 Earnings Call Highlights: Strategic Advances and ...
Cathie Wood's ARK Sheds Robinhood Stock, Adds to Amazon and Coinbase
Truist Financial Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
Truist Financial Initiates a Buy Rating on Intellia Therapeutics (NTLA)
Intellia Therapeutics' Gene Editing Potential Bolsters Buy Rating Amidst Promising HAELO Study Progress
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $41
Intellia Therapeutics Launches Phase 3 Trial of Investigational Hereditary Angioedema Treatment
Express News | Intellia Therapeutics Announces Initiation of Haelo Phase 3 Study of Ntla-2002, an Investigational in Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (Hae)
Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics (NASDAQ:NTLA Shareholders Incur Further Losses as Stock Declines 10% This Week, Taking Three-year Losses to 86%
Wells Fargo Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $95
Institutional Owners May Consider Drastic Measures as Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Recent US$92m Drop Adds to Long-term Losses
Intellia Therapeutics to Present New Clinical Data From the Phase 1 Study of Nexiguran Ziclumeran (Nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
RBC Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $54
RBC Capital analyst Luca Issi maintains $Intellia Therapeutics(NTLA.US)$ with a buy rating, and maintains the target price at $54.According to TipRanks data, the analyst has a success rate of 22.6%